Showing Latest Articles
Age at treatment predicts reason for discontinuation of TNF antagonists: Data from the BIOBADASER 2.0 registry
Rheumatology, 08/24/2011
Clinical Article
Busquets N et al. – Factors predicting discontinuation of TNF antagonists due to AEs are older age and diagnosis of RA. Younger age predicts discontinuation due to lack of efficacy.
Methods- All patients treated with TNF antagonists in BIOBADASER 2.0, with a diagnosis of either RA or spondyloarthritis (SpA: AS and PsA) were included and classified as <65 (younger) or ≥65 years of age (older) at start of treatment
- Cumulative incidence function for discontinuation (inefficacy or AE) was estimated as being alternative reason for competing risk
- Competing-risks regression models used to measure association between study groups, covariates and reason for discontinuation
- 4851 patients were studied; 2957 RA (2291 in the younger group and 666 in the older group) and 1894 SpA (1795 in the younger group and 99 in the older group)
- Retention curves were statistically differently stratified by age groups, with the SpA younger group having the largest retention rate
- Competing-risks regression models showed that in older group, AEs were most common reason for discontinuation regardless of diagnosis of patient and TNF antagonist molecule
- In younger group, most common cause of discontinuation was inefficacy